Winston Pharmaceuticals FCF per Share
The Free Cash Flow per Share of Winston Pharmaceuticals (WPHM) as of Oct 30, 2026 is -0.07 USD.
Get this data via API
Financial Data API
FCF per Share
-0.07USD
Last updated:
Free Cash Flow per Share of Winston Pharmaceuticals is 2009 -0.07 USD. Free Cash Flow per Share of Winston Pharmaceuticals was 2008 - USD. It decreases by % lower compared to the previous year.
The Winston Pharmaceuticals FCF per Share history
| YEAR | FCF per Share | YoY |
|---|---|---|
| -0.07USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Winston Pharmaceuticals Stock analysis
What does Winston Pharmaceuticals do? Winston Pharmaceuticals Inc is a pharmaceutical company based in the USA, focused on drug development and marketing. The company was founded in 1999 and has since built a successful history in the industry.
The business model of Winston Pharmaceuticals is to develop and market innovative drugs that enable sustainable improvement in the health and quality of life of patients. The company invests in research and development, as well as clinical testing of its products, to ensure effectiveness and safety.
Winston Pharmaceuticals is divided into various divisions, including oncology, cardiovascular, and neuropsychiatric disorders. Each division focuses on specific areas of disease to allow for targeted and focused research and development strategies.
In the oncology division, Winston Pharmaceuticals focuses on developing drugs for the treatment of cancer types such as breast, prostate, and lung cancer. The company has a range of products in different stages of development, including the emerging cancer drug candidate WPH-333.
In the cardiovascular division, Winston Pharmaceuticals has developed a range of drugs that can be used to treat conditions such as hypertension, angina, heart failure, and thromboembolism. The company also focuses on researching the pathophysiology of cardiovascular diseases to develop new therapeutics.
In the neuropsychiatric division, Winston Pharmaceuticals develops drugs for the treatment of disorders such as schizophrenia, depression, and anxiety. The company is also involved in the development of novel drugs for the treatment of brain injuries and diseases such as Alzheimer's.
Some of Winston Pharmaceuticals' most well-known products include Insidon, an antidepressant, Limbitrol, a medication for the treatment of depression, and Wolfsbane, a calming antipsychotic. The company has also recently launched the medication WPH-231 for the treatment of schizophrenia.
In terms of regulatory affairs, Winston Pharmaceuticals works closely with regulatory authorities to ensure compliance with all regulations and approval requirements. The company places great emphasis on quality and safety, ensuring that all products meet the highest industry standards.
Winston Pharmaceuticals has made a name for itself in the industry due to its extensive experience, top-notch research team, and innovative capabilities. The company aims to provide patients worldwide with the best drugs while maintaining responsible and sustainable business practices.
Overall, Winston Pharmaceuticals is an emerging company in the pharmaceutical industry that will produce many promising products due to its extensive research and development activities and focus on targeted disease areas. Winston Pharmaceuticals is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Winston Pharmaceuticals stock
Free Cash Flow per Share of Winston Pharmaceuticals is -0.07 USD in 2009.
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Winston Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Winston Pharmaceuticals
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Winston Pharmaceuticals
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth